Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.

Platelet-activating factor (PAF) acetylhydrolase has been recognized as an enzyme that inactivates PAF. We developed a convenient and reproducible method for determining human serum PAF acetylhydrolase activity. The assay was based on measurement of [14C]acetate produced from 1-O-alkyl-2-[14C]-acetyl-sn-glycero-3-phosphocholine upon precipitation of the complex of radioactive substrate and albumin with TCA. The apparent Km value of PAF acetylhydrolase (near the physiological concentration of serum protein) was 1.5 X 10(-4) M PAF. 32 subjects with serum PAF acetylhydrolase deficiency were found among 816 healthy Japanese adults. The low PAF acetylhydrolase activity in the deficient serum might not be due to the presence of enzyme inhibitor. Both the sensitivity to PAF and the metabolism of PAF in platelets from PAF acetylhydrolase-deficient subjects were almost the same as those of normal subjects. Deficiency in serum PAF acetylhydrolase appeared to be transmitted by autosomal recessive heredity among five Japanese families. Among healthy adults, healthy children, and asthmatic children, who were grouped into five classes on the basis of respiratory symptoms (remission, wheezy, mild, moderate, and severe groups), the probability of PAF acetylhydrolase deficiency was significantly higher in groups with severe symptoms (moderate and severe) (P less than 0.01). These results suggest that deficiency of serum PAF acetylhydrolase might be one of the factors leading to severe respiratory symptoms in asthmatic children.

[1]  M. Ohno,et al.  Hydrolysis of platelet activating factor and its methylated analogs by acetylhydrolases. , 1988, Journal of biochemistry.

[2]  B. Schlag,et al.  Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. , 1987, Thrombosis research.

[3]  J. Sugatani,et al.  Platelet-activating factor stimulation of rabbit platelets is blocked by serine protease inhibitor (chymotryptic protease inhibitor). , 1987, The Journal of biological chemistry.

[4]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. , 1987, The Journal of biological chemistry.

[5]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Purification and properties. , 1987, The Journal of biological chemistry.

[6]  D. Agrawal,et al.  Effects of platelet activating factor on the chemotaxis of normodense eosinophils from normal subjects. , 1987, Biochemical and biophysical research communications.

[7]  P. Henson.  Extracellular and Intracellular Activities of PAF , 1987 .

[8]  A. Wardlaw,et al.  Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. , 1986, The Journal of clinical investigation.

[9]  M. Oda,et al.  Polymorphonuclear leukocyte-platelet interactions: acetylglyceryl ether phosphocholine-induced platelet activation under stimulation with chemotactic peptide. , 1986, Journal of biochemistry.

[10]  H. van den Bosch,et al.  Identification of a calcium-independent phospholipase A2 in rat lung cytosol and differentiation from acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF-acether). , 1986, Biochimica et biophysica acta.

[11]  C. Page,et al.  Effects of ketotifen upon responses to platelet activating factor: a basis for asthma prophylaxis. , 1986, Annals of allergy.

[12]  L. McManus.  Pathobiology of platelet-activating factors. , 1986, Pathology and immunopathology research.

[13]  T. Miyake,et al.  [Analysis of wheezy children in elementary school. Prevalence of wheeze, bronchial asthma, and correlation between serum IgE levels, RAST score to mite and severity of respiratory symptoms]. , 1985, Arerugi = [Allergy].

[14]  Margaret S. Wu,et al.  Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. , 1985, Biochemical and biophysical research communications.

[15]  F. Snyder,et al.  Inactivation of platelet activating factor by rabbit platelets. Lyso-platelet activating factor as a key intermediate with phosphatidylcholine as the source of arachidonic acid in its conversion to a tetraenoic acylated product. , 1985, Journal of Biological Chemistry.

[16]  R. Wykle,et al.  1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. , 1984, The Journal of biological chemistry.

[17]  R. Patterson,et al.  Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. , 1984, The Journal of laboratory and clinical medicine.

[18]  L. McManus,et al.  Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[19]  G. Camussi,et al.  Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells. , 1983, Journal of immunology.

[20]  H. Homma,et al.  The metabolism of platelet activating factor in platelets and plasma of various animals. , 1983, The Journal of toxicological sciences.

[21]  J. O'flaherty,et al.  Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. , 1983, The Journal of biological chemistry.

[22]  F. Snyder,et al.  Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats. , 1983, Biochemical and biophysical research communications.

[23]  J. O'flaherty,et al.  Metabolic fate of platelet-activating factor in neutrophils. , 1983, The Journal of biological chemistry.

[24]  J. Heffner,et al.  Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. , 1983, The Journal of clinical investigation.

[25]  E. Lapetina.  Platelet-activating factor stimulates the phosphatidylinositol cycle. Appearance of phosphatidic acid is associated with the release of serotonin in horse platelets. , 1982, Journal of Biological Chemistry.

[26]  F. Snyder,et al.  Activities of enzymes that metabolize platelet-activating factor (1-Alkyl-2-acetyl-sn-glycero-3-phosphocholine) in neutrophils and eosinophils from humans and the effect of a calcium ionophore. , 1982, Biochemical and biophysical research communications.

[27]  L. McManus,et al.  Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[28]  D. Hanahan,et al.  Induction of leukocytic infiltrates in rabbit skin by acetyl glyceryl ether phosphorylcholine. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[29]  A. Marcus,et al.  Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro. , 1981, Blood.

[30]  J. O'flaherty,et al.  Anaphylactic actions of platelet-activating factor. , 1981, The American journal of pathology.

[31]  L. Lichtenstein,et al.  Contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. , 1981, The American journal of physiology.

[32]  J. O'flaherty,et al.  1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. , 1981, The American journal of pathology.

[33]  L. McManus,et al.  Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. , 1981, The Journal of clinical investigation.

[34]  F. Snyder,et al.  A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). , 1981, The Journal of biological chemistry.

[35]  J. Benveniste,et al.  Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Palmer,et al.  Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit. , 1980, The American review of respiratory disease.

[37]  J. Liehr,et al.  Identification of platelet activating factor isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine. , 1980, The Journal of biological chemistry.

[38]  R. Farr,et al.  Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF). , 1980, Clinical immunology and immunopathology.

[39]  F. Snyder,et al.  Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. , 1979, Biochemical and biophysical research communications.

[40]  D. Hanahan,et al.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.

[41]  D. Hanahan,et al.  Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. , 1979, Journal of immunology.

[42]  J. Cazenave,et al.  Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. , 1979, Laboratory investigation; a journal of technical methods and pathology.

[43]  P. Henson,et al.  The release of a platelet-activating factor by stimulated rabbit neutrophils. , 1979, Journal of immunology.

[44]  E. Weber.  McKusick, V. A.: Human Genetics, 3. Neudruck. Foundations of Modern Genetics Series. Prentice Hall Internat., Inc. Englewood Cliffs, New Jersey 1965. XII + 148 S., 67 Abb. , 1968 .

[45]  E. E. Muirhead,et al.  Renal autoexplantation and protection against renoprival hypertensive cardiovascular disease and hemolysis. , 1960, The Journal of clinical investigation.

[46]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.